Natural bioactive products in the regulation of bone metabolism and regeneration
Open Access
- 14 November 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1683279
Abstract
Osteoporosis (OP) is a systemic skeletal disorder characterized by decreased bone mineral density (BMD), impaired bone microarchitecture, and an elevated risk of fragility fractures. Although conventional pharmacological agents—such as bisphosphonates, selective estrogen receptor modulators, and monoclonal antibodies—can attenuate disease progression, their long-term application is limited by adverse effects and suboptimal patient adherence. Consequently, there is growing interest in the development of safer, multi-targeted therapeutic strategies. Plant-derived bioactive products have garnered increasing attention due to their broad pharmacological profiles, including the promotion of osteoblastogenesis, suppression of osteoclastogenesis, regulation of bone–vascular coupling, and modulation of immune and oxidative stress pathways. Recent advances in biomaterial-assisted delivery systems have further improved the physicochemical stability, bioavailability, and tissue-specific delivery of these phytochemicals, thereby enhancing their therapeutic efficacy in bone regeneration. Although accumulated in vitro and in vivo studies suggest the bone-protective potential of these natural agents, clinical translation remains limited. Further mechanistic investigations and rigorously designed clinical trials are warranted to substantiate their efficacy and safety in human populations. This review summarizes recent progress in the mechanistic understanding of natural products involved in bone metabolism, with a particular focus on representative classes such as flavonoids, polyphenols, polysaccharides, glycosides, and terpenoids. In addition, we discuss the translational potential of integrating these agents with advanced drug delivery platforms, aiming to provide a theoretical framework and future research directions for the treatment of OP and related bone disorders.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 158 references indexed in Scilit:
- Osthole accelerates osteoporotic fracture healing by inducing the osteogenesis–angiogenesis coupling of BMSCs via the Wnt/β‐catenin pathwayPhytotherapy Research, 2024
- Picein alleviates oxidative stress and promotes bone regeneration in osteoporotic bone defect by inhibiting ferroptosis via Nrf2/HO‐1/GPX4 pathwayEnvironmental Toxicology, 2024
- The diverse origin of bone-forming osteoblastsJournal of Bone and Mineral Research, 2021
- Neobavaisoflavone protects osteoblasts from dexamethasone‐induced oxidative stress by upregulating the CRNDE‐mediated Nrf2/HO‐1 signaling pathwayDrug Development Research, 2021
- Canonical Notch signaling is required for bone morphogenetic protein-mediated human osteoblast differentiationStem Cells, 2020
- Curcumin prevents osteocyte apoptosis by inhibiting M1‐type macrophage polarization in mice model of glucocorticoid‐associated osteonecrosis of the femoral headJournal of Orthopaedic Research, 2020
- MAP Kinase‐Dependent RUNX2 Phosphorylation Is Necessary for Epigenetic Modification of Chromatin During Osteoblast DifferentiationJournal of Cellular Physiology, 2016
- Dysapoptosis of Osteoblasts and Osteocytes Increases Cancellous Bone Formation But Exaggerates Cortical Porosity With AgeJournal of Bone and Mineral Research, 2013
- Pharmacokinetics of astragalosideiv in beagle dogsEuropean Journal of Drug Metabolism and Pharmacokinetics, 2007
- Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal womenOsteoporosis International, 2004